**METHOD FOR EARLY TAKO-TSUBO CARDIOMIOPHATY PROGNOSIS IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE**

**The Need**
Aneurysmal subarachnoid haemorrhage represents a serious medical emergency with high mortality and morbidity due to early rebleeding. Approximately 11% of these patients die before receiving medical attention and 40% die within 4 weeks after admission to hospital. Among survivors 30% have a considerable limitation for activities of daily living and often suffer from cardiac complications associated with an increased risk of short-term death. Tako-Tsubo cardiomyopathy (TTC) is the main cardio-dysfunction that occurs after neurological damage. The prevalence in SAH’s patients is between 20% and 30%, with a higher prevalence in women. There is a medical need in predicting risk of TTC in early SAH stages in order to adapt accordingly their treatment and monitoring.

**The Solution**
The technology provides an in vitro method able to predict, at day 0 with 100% efficiency, patients with a subarachnoid aneurysmal haemorrhage that will develop a complication of Tako-Tsubo cardiomyopathy and therefore should follow a preventive treatment and monitoring. The solution is based in determining the combined level of two molecules or their mRNA in serum/blood samples obtained from the patient at emergency arrival.

**Innovative Aspects**
- Early prediction of SAH complications into a TTC cardiomyopathy.
- Rapid and easy identification of patients.
- Preventive treatment and monitoring of these patients.
- Reduction of severity effects and mortality.
- Minimally invasive method from serum or blood samples
- The IVD can be easily implemented to be performed in health services’ currently available devices

**Stage of Development:**
The method is currently being validated by the group in a bigger cohort of patients arriving though emergency services at hospitals.

**Intellectual Property:**
- Spanish patent filed (3rd March 2021)

**Aims**
Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.

**Contact details**
Centro de Investigación Biomédica en Red (CIBER)
otc@ciberisciii.es
transferencia@ciberisciii.es
https://www.ciberisciii.es/en